Fluorescent tracer agents coupled with transdermal detection technology enable physiological monitoring.
More >>
Bright fluorescent agents designed not to interact with the body are sensed through the skin.
More >>
New clinical applications for fluorescent tracer agent-based systems are in development.
More >>
Clinical and preclinical studies are underway to advance the use of fluorescence to measure and monitor disease progression.
More >>
Composition of matter, device, algorithm, process and method patents in the US, Europe and globally.
More >>
Leading academic centers, research institutes, contract research organizations and pharmaceutical companies worldwide rely on MediBeacon technology.
More >>
Fluorescent agents engineered to not interact with the body have the potential to enable measurement and monitoring of vital organ systems.
More >>
GFR is widely accepted as the best indicator of kidney function. A clinically practical and accurate point of care methodology holds promise.
More >>
Increased intestinal permeability is implicated in inflammatory bowel disease. Rapid assessment of gut barrier function is a focus.
More >>
Fluorescent agent angiography has the potential to aid in diagnosis and monitoring of vasculature leakage seen in Diabetic Retinopathy, Macular Degeneration and Retinal Vasculitis.
More >>
Intraoperative identification of ureter or ureteral injury is critical to prevent serious complications. Use of fluorescent agents could potentially aid in surgical visualization.
More >>
Potential medical applications for fluorescent tracer agent-based systems are wide ranging and target important unmet patient needs.
More >>
Technology whose development began inside leading medical technology companies is ready for human application.
More >>
Industry leaders including scientists and clinicians are behind fluorescence enabled technology that has the potential to impact global health.
More >>
Investment in fluorescence-based systems target multiple multi-billion dollar unmet medical needs.
More >>
Our approach to quality concentrates on the integrity of processes and preventive measures.
More >>
Shungang Zhang, MS; Joshua D. Breidenbach, MS; Fatimah K. Khalaf, MBCHB; Prabhatchandra R. Dube, PhD; Chrysan J. Mohammed, BA; Apurva Lad, MS; Stanislaw Stepkowski, PhD; Terry D. Hinds, PhD; Sivarajan Kumarasamy, PhD; Andrew Kleinhenz, BS; Jiang Tian, PhD; Deepak Malhotra, MD, PhD; David J. Kennedy, PhD; Christopher J. Cooper, MD; Steven T. Haller, PhD, "Renal Fibrosis Is Significantly Attenuated Following Targeted Disruption of Cd40 in Experimental Renal Ischemia," Journal of the American Heart Association, 2020;9:e014072. DOI: 10.1161/JAHA.119.014072.
United States
MediBeacon Inc.
425 N. New Ballas Road
Suite 100
St. Louis, MO 63141
P: (314) 269-5808
Germany
MediBeacon GmbH
Cubex41
Theodor-Kutzer-Ufer 1-3
68167 Mannheim
P: +49 (0)621-150283-15
Greater China
(Commercial Partner)
Huadong Medicine Co., Ltd
Telephone: 4008-269-985
+86-(0)571-89908581
Zip: 310011
Address: No.866. Moganshan Road, Hangzhou, Zhejiang Province, China
Email: info@eastchinapharm.com
*MediBeacon products are in various stages of development.